Agenus Inc. (NASDAQ:AGEN) Stock Holdings Trimmed by Key Client Fiduciary Advisors LLC

Key Client Fiduciary Advisors LLC lessened its position in shares of Agenus Inc. (NASDAQ:AGEN) by 3.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 67,416 shares of the biotechnology company’s stock after selling 2,338 shares during the period. Key Client Fiduciary Advisors LLC owned about 0.32% of Agenus worth $369,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Point72 DIFC Ltd bought a new stake in shares of Agenus during the 2nd quarter valued at about $51,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Agenus during the second quarter valued at approximately $106,000. Blair William & Co. IL bought a new position in shares of Agenus during the second quarter valued at approximately $441,000. Exchange Traded Concepts LLC raised its position in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock worth $151,000 after purchasing an additional 9,422 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of Agenus in the 2nd quarter worth approximately $614,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on AGEN shares. Jefferies Financial Group reaffirmed a “hold” rating and issued a $7.00 target price (up from $3.00) on shares of Agenus in a research report on Friday, July 19th. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Baird R W lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 19th. B. Riley reduced their price objective on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Finally, William Blair downgraded Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Agenus presently has an average rating of “Hold” and a consensus price target of $10.50.

Agenus Stock Performance

Shares of NASDAQ:AGEN traded up $0.05 during trading hours on Friday, hitting $4.62. 407,989 shares of the company’s stock traded hands, compared to its average volume of 662,212. The company’s fifty day simple moving average is $5.17 and its two-hundred day simple moving average is $9.31. The company has a market cap of $97.02 million, a price-to-earnings ratio of -0.36 and a beta of 1.37. Agenus Inc. has a 52 week low of $4.18 and a 52 week high of $21.20.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The business had revenue of $23.51 million for the quarter, compared to analysts’ expectations of $64.73 million. During the same quarter last year, the business posted ($4.00) EPS. On average, analysts anticipate that Agenus Inc. will post -10.87 EPS for the current fiscal year.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.